Remedica
Max Sorokin is an accomplished finance professional with extensive experience in senior leadership roles. Currently serving as Chief Financial Officer at Remedica since May 2025, Sorokin previously held the same position at Acino from September 2019 to May 2025. Sorokin's earlier career includes significant roles at PepsiCo, where responsibilities included Head of Group Commercial Finance and various senior management positions focused on supply chain finance and financial planning and analysis from May 2013 to July 2019. Additionally, Sorokin served as Associate Director of Licensing & Business Development at Merck Serono from September 2010 to August 2012 and worked as a Consultant/Talent Partner in the life sciences practice at a-connect from February 2009 to June 2010. Academic credentials include an MBA from IMD and a BA in Economics, Business, and German from Wabash College.
This person is not in any teams
This person is not in any offices
Remedica
Remedica, is a leading pharmaceutical company, with export activities in more than 160 countries. Originally founded in 1960 by Mr. Takis Pattichis, Remedica specialises in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. Furthermore, Remedica offers out-licensing opportunities and its product portfolio consists of Antineoplastic agents, Antivirals, Aromatase inhibitors, Antiinfectives, products for the nervous system, products for the cardiovascular system, dermatologicals, antimalarials, and has pipeline consisting of more Therapeutic Categories. Currently, Remedica has 5 state-of-the-art factories all of which have been routinely inspected and approved by the health authorities of several European Union Member States including Cyprus, Germany, and Denmark as well as those of United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA) and many more. Remedica invests in product development, in innovation and technology, and in human resources, and encourages the progress of science, education and health. Remedica’s Corporate Social Responsibility (CSR) commitment is built on its vision, strategies and mission. It is based on its core business, operating background, stakeholder’s outlooks and company’s culture. By providing safe, efficacious and high quality pharmaceuticals at affordable prices, Remedica has improved the health and saved the lives of millions of people who may otherwise have had to pay more or who may not have been in a position to afford a more expensive treatment. To meet this commitment the company implements management systems in its operations that accord with the requirements of its CSR standards. Remedica’s CSR is based on various parameters which include but are not limited to Environment, Human Resources, Society and Education.